Selank for Anxiety: Reading the Actual Evidence
Selank is a synthetic peptide, an analogue of the immunomodulator tuftsin, studied in Russia primarily as an anxiolytic and nootropic candidate. It is sometimes confused with Semax, a structurally different peptide from the same research tradition; the two are not interchangeable and have different study bases (see our Semax vs. Selank comparison). This page focuses narrowly on the anxiety evidence: what was studied, in whom, and what the studies can and cannot tell a reader.
What is the core claim, and what actually supports it?
The strongest human evidence is a set of Russian clinical studies in patients with generalized anxiety disorder (GAD) and related conditions, comparing Selank to placebo or to phenazepam, a benzodiazepine used in Russia. One study reports that Selank produced anxiolytic effects with a tolerability profile the authors judged favorable relative to phenazepam (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014). A related paper on treatment optimization in anxiety disorders reports similar directional findings (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015). An earlier paper describes efficacy and proposed mechanisms in GAD and neurasthenia specifically (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008).
These are the load-bearing citations for the "Selank helps anxiety in humans" claim. They are also the papers where the least methodological detail is available in English-language abstracts: precise sample sizes, randomization method, blinding, and pre-registration are not verifiable from the abstract level, and full-text critical appraisal has not been done for this page. Treat these as suggestive clinical evidence from a single research tradition, not as guideline-grade trials that have been through FDA or independent international peer review at the level applied to approved anxiolytics.
Does the comparison to phenazepam mean Selank works "as well as" a benzodiazepine?
Not established. A head-to-head comparison exists (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014), and it is the closest thing to a comparative-efficacy claim in the available literature. But "compared favorably in one study population" is different from "clinically equivalent." Phenazepam itself is not an FDA-approved drug in the United States, so this comparison does not map onto any US-approved treatment pathway. Readers weighing Selank against an FDA-approved option like an SSRI are working with a different evidence base entirely; see our Selank vs. SSRIs comparison for that distinction, and use the FDA Peptide Status Tracker to check current regulatory status before assuming any equivalence.
What does the animal and mechanistic evidence add, and what are its limits?
Most of the Selank literature is preclinical, and it is genuinely more mechanistically detailed than the human trials. Rodent studies report anxiolytic-like behavioral effects, including in a tuftsin-analogue model with long-term dosing and effects on body weight (Pharmacological Reports, 2006), and effects on apomorphine-induced behaviors that were blocked by naloxone, suggesting an opioid-system contribution to the anxiolytic effect (Bulletin of Experimental Biology and Medicine, 2006). A follow-up paper further examines the opioid system's role in Selank's anti-anxiety action specifically (Eksperimental'naia i klinicheskaia farmakologiia, 2012).
Other rodent work looks at depression-like and stress-related behaviors across strains (WAG/Rij, Wistar, BALB/c) (Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2008), monoamine content changes in mouse brain (Eksperimental'naia i klinicheskaia farmakologiia, 2008), and an enhancement of diazepam's anxiolytic effect under chronic mild stress in rats (Behavioural Neurology, 2017). GABAergic gene expression effects have been studied in a human neuroblastoma cell line alongside GABA and olanzapine (Frontiers in Pharmacology, 2017), and synaptic activity effects have been recorded in rat hippocampal neurons (Bulletin of Experimental Biology and Medicine, 2017). A broader mechanistic review summarizes proposed molecular pathways (Protein and Peptide Letters, 2018); see also our mechanism page for a fuller walkthrough.
This is a coherent mechanistic story across species and methods. It is not the same as confirmed efficacy in humans at scale. Rodent anxiolytic-like behavior (elevated plus maze performance, reduced defensive behaviors) does not reliably predict human clinical response for every compound that shows it; that gap is exactly why regulators require human trials before approval, and Selank has not gone through that process for any indication.
Where does the evidence stop being reassuring?
Three boundaries matter for a reader deciding what to make of this literature.
Population. Almost all of the human studies come from a specific clinical and research context (Russian psychiatric practice, GAD and neurasthenia diagnoses). Whether findings generalize to other anxiety presentations, other diagnostic frameworks, or non-Russian patient populations is not established.
Trial design detail. Sample sizes in the available abstracts are small by modern RCT standards, and abstract-level reporting does not confirm randomization concealment, blinding of raters, or pre-specified outcomes. This matters because unblinded or poorly randomized anxiety trials are prone to inflated placebo-adjacent effects.
Independent replication. The anxiolytic human trials largely originate from overlapping research groups and journals. Independent replication outside that tradition, including in an FDA-reviewed trial framework, has not occurred as far as the available evidence shows.
None of this means the preclinical mechanism is wrong or that the human trials are fabricated. It means the evidence sits below the level required for approval anywhere, and readers should not treat "studied in humans" as equivalent to "proven effective and safe."
A framework for weighing a single anxiolytic study
Because most Selank anxiety claims trace back to a handful of papers, it helps to run each one through the same short checklist before deciding how much weight it deserves.
Selank study weight-of-evidence checklist
| Question | Why it matters | Answerable from current abstracts? |
|---|---|---|
| Was there a placebo or active comparator arm? | Distinguishes drug effect from natural symptom fluctuation | Partially, phenazepam comparator exists in some papers |
| Was allocation randomized and blinding described? | Prevents rater or patient expectation bias | Not verifiable from abstract level |
| What was the sample size and was it powered? | Small samples inflate apparent effect sizes | No power calculation reported in accessible abstracts |
| Is the population defined (diagnosis, severity)? | Determines who findings might apply to | Partially, GAD and neurasthenia noted in some studies |
| Has an independent group replicated the result? | Reduces risk of single-lab or single-country artifact | Not established in current literature |
| Does the mechanism have converging preclinical support? | Increases biological plausibility even without confirmed clinical efficacy | Yes, opioid and GABAergic pathway data exist |
A study that only clears one or two rows should be read as hypothesis-generating, not as proof of efficacy. None of the currently available Selank anxiety studies clear more than three or four rows based on what is accessible without full-text methodological review.
What about safety signals in these same studies?
The anxiety trials and related pharmacology studies report tolerability observations (for example, favorable tolerability relative to phenazepam), and separate animal work looks at gastric mucosal effects (Bulletin of Experimental Biology and Medicine, 2007) and immune-related gene expression changes (Genetika, 2011). These are not a substitute for a dedicated safety review. For contraindications, adverse effect patterns, and what would warrant stopping use and seeking care, see our side effects and safety page rather than relying on efficacy-study safety asides.
Practical bottom line
If you are trying to decide whether Selank's anxiolytic evidence is strong enough to guide a health decision, the honest answer is: it is more than a rumor and less than a proven treatment. The human trials point in a consistent direction within a narrow research context, and the preclinical mechanism work is unusually detailed for a peptide at this stage of development. But there is no FDA approval, no confirmed regulatory pathway, and no independent large-scale replication. Anyone considering Selank should treat it as an unapproved substance with limited, geographically concentrated human evidence, not as a validated alternative to FDA-approved anxiety treatments, and should talk to a licensed clinician about approved options and about what individualized dosing or diagnosis questions require in-person evaluation rather than general information. Sudden severe anxiety, panic symptoms with chest pain or shortness of breath, or thoughts of self-harm warrant urgent in-person care, not a peptide decision.
For the regulatory picture behind these numbers, see Selank's FDA status and the FDA Peptide Status Tracker. For a broader look at how to grade peptide evidence generally, see how we assess Selank evidence quality.